Augmentation strategies for treatment of unipolar major depression

Modern Problems of Pharmacopsychiatry

Volumn 25, Issue , 1997, Pages 34-55

  Nelson, J Craig ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

CLASSIFICATION; DEPRESSION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; HUMAN; PSYCHOLOGICAL ASPECT; REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; TREATMENT OUTCOME;

EID: 0030627042     PISSN: 00770094     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000061657     Document Type: Review

References (74)

1. APA: Practice guideline for major depressive disorder in adults. Am J Physchiatry 1993;150;4(suppl):1-26
2. Rush AJ, Trivedi MJ: Treating depression to remission. Psychiatr Ann 1995:25:704-709.
3. Nelson JC: Importance of intent-to-treat response rates for the clinician. Psychiatr Ann 1996;26:8-18.
4. Agency for Health Care Policy and Research: Clinical Practice Guideline: Depression in Primary Care: Treatment of Major Depression, vol 2. Rockville, US Government Printing Office, 1993.
5. Nelson JC: Combined treatment strategies in psychiatry. J Clin Psychiatry 1993;54;9(suppl):42-49.
6. Delgado PL, Price LH, Charney DS, et al: Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 1988;15:55-60.
7. DeMontigny C, et al: Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Arch Gen Psychiatry 1983;40:1327-1334.
8. Jones JS, Stanley M: Sertonergic agents in the treatment of refractory depression; in Roose SP, Glassman AH (eds): Treatment Strategies for Refactory Depression.Washington, American Psychiatric Press, 1990.
9. Thomson J, Rankin H, Ashcroft GW, Yates CM, McQueen JK, Cummings SW: The treatment of depression in general practice: A comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo. Psychol Med 1982;12:741-751.
10. CMB Pare: Potentiation of monoamine-oxidase inhibitors by tryptophan (letter). Lancet 1963;ii:527-528.
11. Prange AJ, Wilson IC, Rabon AM, et al: Enhancement of imipramine anti-depressant activity by thyroid hormone. Am J Psychiatry 1969;126:457-469.
12. Joffe RT, Sokolov STH: Thyroid hormones, the brain, and affective disorders. Crit Rev Neurobiol 1994;8(1/2):45-63.
13. Goodwin FK, Prange AJ, Post RM, et al: Potentiation of antidepressant effects by L-triiodotyronine in tricyclic nonresponders. Am J Psychiatry 1982;139:34-38.
14. Thase ME, Kupfer DJ, Jarrett DB: Treatment of imipramine-resistant recurrent depression: I. An open clinical trial of adjunctive L-triidothyronine. J Clin Psychiatry 1989;50:385-388.
15. 3 to potentiate tricyclic antidepressant response. J Affect Disord 1987;13:267-272.
16. Joffe RT, Singer W, Levitt AJ, MacDonald C: A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-393.
17. Joffe RT, Singer W: A comparison of triiodothyronine and thyroxine in the potentiation of tricylic antidepressants. Psychiatry Res 1990;32:241-251.
18. Joffe RT: Triiodothyronine potentiation of fluoxetine in depressed patients. Can J Psychiatry 1992;37:48-50.
19. Bauer MS, Whybrow PC: Thyroid hormones and the central nervous system in affective illness: Interactions that may have clinical significance. Integr Psychiatry 1988;6:75.
20. DeMontigny C, Grunberg F, Mayer A, Deschenes JP: Lithium induces rapid relief of depression in tricyclic antidepressant drug nonresponders. Br J Psychiatry 1981;138:252-256.
21. Nelson JC: Use of lithium augmentation in refractory depression; in Roose S, Glassman A (eds): Treatment Strategies in Refractory Depression. Washington, American Psychiatric Press, 1990, pp 35-49.
22. Heninger GR, Charney DS, Sternberg DE: Lithium carbonate augmentation of antidepressant treatment: An effective prescription for treatment-refractory depression. Arch Gen Psychiatry 1983;40:1335-1342.
23. Cournoyer G, DeMontigny D, Ouellette J, Leblanc G, Langlois R, Elie R: Lithium addition in tricyclic-resistant unipolar depression: A placebo-controlled study. 14th Congr Coll Int Neuro-Psychopharmacol (CINP). Florence, June 19-23,1984.
24. Kantor D, McNevin S, Leichner P, Harper D, Krenn M: The benefit of lithium carbonate adjunct in refractory depression - fact or fiction? Can J Psychiatry 1986;31:416-418
25. Zusky PM, Biederman J, Rosenbaum JF, Manschreck TC, Gross CC, Weilberg JB, Gastfriend DR: Adjunct low dose lithium carbonate in treatment-resistant depression: A placebo-controlled study. J Clin Psychopharmacol 1988;8:120-124.
26. Schopf J, Baumann P, Lemarchand T, Rey M: Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition. Results of a placebo-controlled double-blind study. Pharmacopsychiatry 1989;22:183-187.
27. Stein G, Bernadt M: Lithium augmentation therapy in tricyclic-resistant depression: A controlled trial using lithium in low and normal doses. Br J Psychiatry 1993;162:634-640.
28. Katona CLE, Abou-Saleh MT, Harrison DA, Nairac BA, Edwards DRL, Lock T, Burns RA, Robertson MM: Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995;166:80-86.
29. Ontiveros A, Fontaine R, Elie R: Refractory depression: The addition of lithium to fluoxetine or desipramine. Acta Psychiatr Scand 1991;83:188-192.
30. Lingaerde O, Edlund AH, Gormsen CA, Gottfries CG, Haugstad A, Hermann IL, Hollnagel P, Makimattila A, Rasmussen KE, Remvig J, Robak OH: The effect of lithium carbonate in combination with tricyclic antidepressants in endogenous depression. Acta Psychiatr Scand 1974;50:233-242.
31. Price LH, Cappiello AC, McDougle CJ, Malison RT, Charney DS, Heninger GR: Lithium plus desipramine versus desipramine alone in the treatment of major depression: A controlled study. Annu Meet APA, May 23, 1995.
32. Price LH, Charney DS, Heninger G: Variability of response to lithium augmentation in refractory depression. Am J Psychiatry 1986;143:1387-1392.
33. Thase ME, Kupfer DJ, Frank E, Jarrett DB: Treatment of imipramine-resistant recurrent depression: II. An open clinical trial of lithium augmentation. J Clin Psychiatry 1989;50:413-417.
34. Nelson JC, Mazure C: Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry 1986;143:363-366.
35. Satel SL, Nelson JC: Stimulants in the treatment of depression: A critical overview. J Clin Psychiatry 1989;50:241-249.
36. Ayd FJ Jr, Zohar J: Psychostimulant (amphetamine or methylphenidate) therapy for chronic and treatment-resistant depression; in Zohar J, Belmaker RH (eds): Treating Resistant Depression. New York, PMA Publishing, 1987, pp 343-355.
37. Wharton RN, Perel JM, Dayton PG, Malitz S: A potential clinical use of methylphenidate with tricyclic antidepressants. Am J Psychiatry 1971;127:55-61.
38. Drimmer EJ, Gitlin MJ, Gwirtsman HE: Desipramine and methlyphenidate combination treatment for depression: Case report. Am J Psychiatry 1983;140:241-242.
39. Fawcett J, Kravitz HM, Zajecka JM, Schaff MR: CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991;11:127-132.
40. Jacobsen FM: Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991;52:217-220.
41. Bakish D: Fluoxetine potentiation by buspirone: Three case histories. Can J Psychiatry 1991;36:749-750.
42. Joffe RT, Schuller DR: An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993;54:269-271.
43. Blier P, de Montigny C, Chaput Y: Modification of the serotonin system by antidepressant treatments: Implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987;7:24S-35S.
44. Artigas F, Perez V, Alvarez: Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-251.
45. Blier P, Bergeron R: Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995;15:217-222.
46. Berman RM, Darnell AM, Miller HL, Charney DS: Double-blind placebo-controlled trial of pindolol in depression. Annu Meet APA, May 22, 1995.
47. Lader M: Combined use of tricyclic antidepressants and monoamine oxidase inhibitors. J Clin Psychiatry 1983;44(9, Sec 2):20-24.
48. Devlin MJ, Walsh BT: Use of monoamine oxidase inhibitors in refractory depression; in Tasman A, Goldfinger SM, Kaufman CA (eds): American Psychiatric Press Review of Psychiatry, vol 9. Washington, American Psychiatric Press, 1990, pp 74-90.
49. Goldberg RS, Thornton WE: Combined tricyclic-MAOI therapy for refractory depression: A review, with guidelines for appropriate usage. J Clin Pharmacol 1978;18:143-147.
50. Schuckit M, Robins E, Feighner J: Tricyclic antidepressants and monoamine oxidase inhibitors; Combination therapy in the treatment of depression. Arch Gen Psychiatry 1971;24:509-514.
51. Pare CMB, Mousawi MA, Sandler M, Glover V: Attempts to attenuate the 'cheese effect': Combined drug therapy in depressive illness. J Affect Disord 1985;9:137-141.
52. Young JPR, Lader MH, Hughes WC: Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. Br Med J 1979;ii:1315-1317.
53. Boyer WF, Feighner JP: The combined use of fluoxetine and bupropion. Annu Meet APA, May 27, 1995.
54. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K: Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report. J Clin Psychiatry 1989;50:447-449.
55. Nelson JC, Mazure CM, Bowers MB, Jatlow PI: A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307.
56. Seth R, Jennings AL, Bindman J, et al: Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992;161:562-565.
57. Fava M, Rosenbaum JF, Grossbard SJ, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM: Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double blind, controlled study. Am J Psychiatry 1994;151:1372-1374.
58. Price LH, Charney DS, Delgado PL, Heninger GR: Fenfluramine augmentation in tricyclic-refractory depression. J Clin Psychopharmacol 1990;10:312-317.
59. Charney DS, Price LH, Heninger GR: Desipramine-yohimbine combination treatment of refractory depression. Arch Gen Psychiatry 1986;43:1155-1161.
60. Oppenheim G, Zohar J, Shapiro B, Belmaker RH: The role of estrogen in treating resistant depression; in Zohar J, Belmaker RH (eds): Treating Resistant Depression. New York, PMA Publishing, 1987, pp 357-366.
61. Price LH, Charney DS, Heninger GR: Reserpine augmentation of desipramine in refractory depression: Clinical and neurobiological effects. Psychopharmacology (Berl) 1987;92:431-437.
62. Nierenberg AA: Treatment choice after one antidepressant fails: A survey of northeastern psychiatrists. J Clin Psychiatry 1991;52:383-385.
63. Dornseif BE, Dunlop SR, Potvin JH,Wernicke JF: Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 1989;25:71-79.
64. Nierenberg AA, Fava M, Alpert J, Worthington J, Rosenbaum J: Early non-response to fluoxetine predicts poor eight week outcome. Am J Psychiatry, in press.
65. McGrath PJ, et al: Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull 1987;23:169-172.
66. Nolen WA, van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, Haffmans J: Treatment strategy in depression: II MAO inhibitors in depression resistant to cyclic antidepressants. Acta Psychiatry Scand 1988;78:676-683.
67. Thase ME, Malinger AG, McKnight D, Himmelhoch JM: Treatment of imipramine-resistant recurrent depression. IV. A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992;149:195-198.
68. Reimherr FW, Wood DR, Byerley B, Brainard J, Grosser BI: Characteristics of responders to fluoxetine. Psychopharmacol Bull 1984;20:70-72.
69. Beasley CM Jr, Sayler ME, Cunningham GE, Weiss AM, Masica DN: Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord 1990;20:193-200.
70. Cole JO, Schatzberg AF, Sniffin C, Zolner J, Cole JP: Trazadone in treatment-resistant depression: An open study. J Clin Psychopharmacol 1981;1:49-54.
71. Brown WA, Harrison W: Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacol Bull 1992;28:253-256.
72. Apter JT, Thase ME, Birkett M: Fluoxetine treatment in depressed patients who failed treatment with sertraline. Am Soc Clin Psychopharmacol Present's Day Educational Program. Montego Bay, Feb 18, 1986.
73. Thase ME, Rush AJ, Kasper S, Nemeroff CB: Tricyclics and newer antidepressant medications: Treatment options for treatment-resistant depressions. Depression 1995;2:152-168.
74. Nierenberg AA, Price LH, Charney DS, Heninger GR: After lithium augmentation: A retrospective follow-up of patients with antidepressant- refractory depression. J Affect Disord 1990;18:167-175.